These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 24055993)

  • 1. The costs of identifying undiagnosed prostate cancer in asymptomatic men in New Zealand general practice.
    Lao C; Brown C; Obertová Z; Edlin R; Rouse P; Hodgson F; Holmes M; Gilling P; Lawrenson R
    Fam Pract; 2013 Dec; 30(6):641-7. PubMed ID: 24055993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Screening for prostate cancer in New Zealand general practice.
    Zuzana O; Ross L; Fraser H; Charis B; Alistair S; Leanne T; Michael H; Peter G
    J Med Screen; 2013 Mar; 20(1):49-51. PubMed ID: 23612467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current and projected annual direct costs of screening asymptomatic men for prostate cancer using prostate-specific antigen.
    Krahn MD; Coombs A; Levy IG
    CMAJ; 1999 Jan; 160(1):49-57. PubMed ID: 9934343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PSA screening in New Zealand: total population results and general practitioners' current attitudes and practices.
    van Rij S; Dowell T; Nacey J
    N Z Med J; 2013 Aug; 126(1381):27-36. PubMed ID: 24150262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PSA testing in general practice.
    Hodgson F; Obertová Z; Brown C; Lawrenson R
    J Prim Health Care; 2012 Sep; 4(3):199-204. PubMed ID: 22946067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels <4.0 ng/mL.
    Faria EF; Carvalhal GF; dos Reis RB; Tobias-Machado M; Vieira RA; Reis LO; Nogueira L; Machado RD; Freitas CH; Magnabosco WJ; Mauad EC; Carvalho AL
    BJU Int; 2012 Dec; 110(11 Pt B):E653-7. PubMed ID: 22892057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Informed decision making on PSA testing for the detection of prostate cancer: an evaluation of a leaflet with risk indicator.
    van Vugt HA; Roobol MJ; Venderbos LD; Joosten-van Zwanenburg E; Essink-Bot ML; Steyerberg EW; Bangma CH; Korfage IJ
    Eur J Cancer; 2010 Feb; 46(3):669-77. PubMed ID: 20022239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Economic Analysis.
    Tawfik A
    Ont Health Technol Assess Ser; 2015; 15(11):1-37. PubMed ID: 26366237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate-specific antigen (PSA) screening and follow-up investigations in Māori and non-Māori men in New Zealand.
    Obertová Z; Scott N; Brown C; Hodgson F; Stewart A; Holmes M; Lawrenson R
    BMC Fam Pract; 2014 Aug; 15():145. PubMed ID: 25154420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of Prostate Health Index for prostate cancer detection.
    Nichol MB; Wu J; Huang J; Denham D; Frencher SK; Jacobsen SJ
    BJU Int; 2012 Aug; 110(3):353-62. PubMed ID: 22077934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rural-Urban Differences in Prostate-Specific Antigen (PSA) Screening and Its Outcomes in New Zealand.
    Obertová Z; Hodgson F; Scott-Jones J; Brown C; Lawrenson R
    J Rural Health; 2016; 32(1):56-62. PubMed ID: 26174590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Difference in willingness-to-pay for prostate cancer screening between ill-informed and well-informed men: a contingent valuation survey.
    Yasunaga H; Sugihara T; Imamura T
    Urology; 2011 Jun; 77(6):1325-9. PubMed ID: 21507471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of percent free PSA for prostate cancer detection in men with a total PSA of 4-10 ng/ml.
    Bermúdez-Tamayo C; Martín Martín JJ; González Mdel P; Pérez Romero C
    Urol Int; 2007; 79(4):336-44. PubMed ID: 18025853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost implications of PSA screening differ by age.
    Rao K; Liang S; Cardamone M; Joshu CE; Marmen K; Bhavsar N; Nelson WG; Ballentine Carter H; Albert MC; Platz EA; Pollack CE
    BMC Urol; 2018 May; 18(1):38. PubMed ID: 29743049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Budget impact analysis of a new prostate cancer risk index for prostate cancer detection.
    Nichol MB; Wu J; An JJ; Huang J; Denham D; Frencher S; Jacobsen SJ
    Prostate Cancer Prostatic Dis; 2011 Sep; 14(3):253-61. PubMed ID: 21537346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate-specific antigen testing in Ontario: reasons for testing patients without diagnosed prostate cancer.
    Bunting PS; Goel V; Williams JI; Iscoe NA
    CMAJ; 1999 Jan; 160(1):70-5. PubMed ID: 9934349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mass screening of 12,027 elderly men for prostate carcinoma by measuring serum prostate specific antigen.
    Zhang HF; Wang HL; Xu N; Li SW; Ji GY; Li XM; Pan YZ; Zhang L; Zhao XJ; Gao HW
    Chin Med J (Engl); 2004 Jan; 117(1):67-70. PubMed ID: 14733776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening for prostate cancer with the prostate-specific antigen test: are patients making informed decisions?
    O'Dell KJ; Volk RJ; Cass AR; Spann SJ
    J Fam Pract; 1999 Sep; 48(9):682-8. PubMed ID: 10498074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of non-structured PSA testing on prostate cancer-specific mortality on New Zealand Māori men.
    Matti B; Nguyen CH; Lyndon MP; Zargar-Shoshtari K
    World J Urol; 2024 Oct; 42(1):558. PubMed ID: 39361189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ethnic and socio-economic disparities in prostate cancer screening: lessons from New Zealand.
    Matti B; Lyndon M; Zargar-Shoshtari K
    BJU Int; 2021 Dec; 128 Suppl 3():11-17. PubMed ID: 32599662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.